Logo image of ABCL

ABCELLERA BIOLOGICS INC (ABCL) Stock Fundamental Analysis

NASDAQ:ABCL - Nasdaq - CA00288U1066 - Common Stock - Currency: USD

3.8  +0.12 (+3.26%)

Premarket: 3.99 +0.19 (+5%)

Fundamental Rating

3

Taking everything into account, ABCL scores 3 out of 10 in our fundamental rating. ABCL was compared to 55 industry peers in the Life Sciences Tools & Services industry. ABCL has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, ABCL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABCL has reported negative net income.
ABCL had a negative operating cash flow in the past year.
In multiple years ABCL reported negative net income over the last 5 years.
In multiple years ABCL reported negative operating cash flow during the last 5 years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

ABCL has a Return On Assets (-12.49%) which is in line with its industry peers.
The Return On Equity of ABCL (-16.41%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -12.49%
ROE -16.41%
ROIC N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABCL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.03 indicates that ABCL is not a great score, but indicates only limited risk for bankruptcy at the moment.
ABCL has a Altman-Z score (2.03) which is comparable to the rest of the industry.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.03
ROIC/WACCN/A
WACC9.04%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

ABCL has a Current Ratio of 10.15. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL has a Current ratio of 10.15. This is amongst the best in the industry. ABCL outperforms 92.73% of its industry peers.
ABCL has a Quick Ratio of 10.15. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL has a Quick ratio of 10.15. This is amongst the best in the industry. ABCL outperforms 92.73% of its industry peers.
Industry RankSector Rank
Current Ratio 10.15
Quick Ratio 10.15
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ABCL have decreased by -7.69% in the last year.
ABCL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.49%.
The Revenue has been growing by 19.97% on average over the past years. This is quite good.
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
Revenue 1Y (TTM)-35.49%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%-57.45%

3.2 Future

ABCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.68% yearly.
ABCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.19% yearly.
EPS Next Y-23.72%
EPS Next 2Y-9.51%
EPS Next 3Y-9.43%
EPS Next 5Y21.68%
Revenue Next Year-35.96%
Revenue Next 2Y3.72%
Revenue Next 3Y13.35%
Revenue Next 5Y45.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as ABCL's earnings are expected to decrease with -9.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.51%
EPS Next 3Y-9.43%

More info and screens

0

5. Dividend

5.1 Amount

ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (6/25/2025, 8:28:00 PM)

Premarket: 3.99 +0.19 (+5%)

3.8

+0.12 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners43.29%
Inst Owner Change6.84%
Ins Owners4.16%
Ins Owner Change0.14%
Market Cap1.13B
Analysts82.67
Price Target8.6 (126.32%)
Short Float %10.12%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.15%
Min EPS beat(2)-3.56%
Max EPS beat(2)29.86%
EPS beat(4)2
Avg EPS beat(4)6.87%
Min EPS beat(4)-9.89%
Max EPS beat(4)29.86%
EPS beat(8)5
Avg EPS beat(8)7.87%
EPS beat(12)6
Avg EPS beat(12)-138.24%
EPS beat(16)7
Avg EPS beat(16)-111.52%
Revenue beat(2)0
Avg Revenue beat(2)-39.76%
Min Revenue beat(2)-44.84%
Max Revenue beat(2)-34.68%
Revenue beat(4)0
Avg Revenue beat(4)-32.14%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)-19.76%
Revenue beat(8)1
Avg Revenue beat(8)-25.36%
Revenue beat(12)2
Avg Revenue beat(12)-20.51%
Revenue beat(16)4
Avg Revenue beat(16)-19.52%
PT rev (1m)-29.76%
PT rev (3m)-28.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.84%
EPS NY rev (1m)-3.03%
EPS NY rev (3m)1.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.28%
Revenue NY rev (1m)-19.51%
Revenue NY rev (3m)-47.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.07
P/FCF N/A
P/OCF N/A
P/B 1.11
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.08
BVpS3.43
TBVpS3.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.49%
ROE -16.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.07%
Cap/Sales 280.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.15
Quick Ratio 10.15
Altman-Z 2.03
F-Score3
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
EPS Next Y-23.72%
EPS Next 2Y-9.51%
EPS Next 3Y-9.43%
EPS Next 5Y21.68%
Revenue 1Y (TTM)-35.49%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%-57.45%
Revenue Next Year-35.96%
Revenue Next 2Y3.72%
Revenue Next 3Y13.35%
Revenue Next 5Y45.19%
EBIT growth 1Y-41.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.4%
EBIT Next 3Y3.49%
EBIT Next 5YN/A
FCF growth 1Y-339.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-158.9%
OCF growth 3YN/A
OCF growth 5YN/A